Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis

Zong-liu Hou, Ying Liu, Xi-Hong Mao, Chuan-yu Wei, Ming-yao Meng, Yung-hong Liu, Zara Zhuyun Yang, Hongmei Zhu, Martin Short, Claude Charles Andre Bernard, Zhi-Cheng Xiao

Research output: Contribution to journalArticleOther

29 Citations (Scopus)

Abstract

There is currently great interest in the use of mesenchymal stem cells as a therapy for multiple sclerosis with potential to both ameliorate inflammatory processes as well as improve regeneration and repair. Although most clinical studies have used autologous bone marrow-derived mesenchymal stem cells, other sources such as allogeneic umbilical cord-derived cells may provide a more accessible and practical supply of cells for transplantation. In this case report we present the treatment of aggressive multiple sclerosis with multiple allogenic human umbilical cord-derived mesenchymal stem cell and autologous bone marrow-derived mesenchymal stem cells over a 4 y period. The treatments were tolerated well with no significant adverse events. Clinical and radiological disease appeared to be suppressed following the treatments and support the expansion of mesenchymal stem cell transplantation into clinical trials as a potential novel therapy for patients with aggressive multiple sclerosis.
Original languageEnglish
Pages (from-to)404 - 407
Number of pages4
JournalCell Adhesion and Migration
Volume7
Issue number5
DOIs
Publication statusPublished - 2013

Cite this

Hou, Zong-liu ; Liu, Ying ; Mao, Xi-Hong ; Wei, Chuan-yu ; Meng, Ming-yao ; Liu, Yung-hong ; Yang, Zara Zhuyun ; Zhu, Hongmei ; Short, Martin ; Bernard, Claude Charles Andre ; Xiao, Zhi-Cheng. / Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. In: Cell Adhesion and Migration. 2013 ; Vol. 7, No. 5. pp. 404 - 407.
@article{2c65ff118e78438f996b45d52dd60853,
title = "Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis",
abstract = "There is currently great interest in the use of mesenchymal stem cells as a therapy for multiple sclerosis with potential to both ameliorate inflammatory processes as well as improve regeneration and repair. Although most clinical studies have used autologous bone marrow-derived mesenchymal stem cells, other sources such as allogeneic umbilical cord-derived cells may provide a more accessible and practical supply of cells for transplantation. In this case report we present the treatment of aggressive multiple sclerosis with multiple allogenic human umbilical cord-derived mesenchymal stem cell and autologous bone marrow-derived mesenchymal stem cells over a 4 y period. The treatments were tolerated well with no significant adverse events. Clinical and radiological disease appeared to be suppressed following the treatments and support the expansion of mesenchymal stem cell transplantation into clinical trials as a potential novel therapy for patients with aggressive multiple sclerosis.",
author = "Zong-liu Hou and Ying Liu and Xi-Hong Mao and Chuan-yu Wei and Ming-yao Meng and Yung-hong Liu and Yang, {Zara Zhuyun} and Hongmei Zhu and Martin Short and Bernard, {Claude Charles Andre} and Zhi-Cheng Xiao",
year = "2013",
doi = "10.4161/cam.26941",
language = "English",
volume = "7",
pages = "404 -- 407",
journal = "Cell Adhesion and Migration",
issn = "1933-6918",
publisher = "Taylor & Francis",
number = "5",

}

Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. / Hou, Zong-liu; Liu, Ying; Mao, Xi-Hong; Wei, Chuan-yu; Meng, Ming-yao; Liu, Yung-hong; Yang, Zara Zhuyun; Zhu, Hongmei; Short, Martin; Bernard, Claude Charles Andre; Xiao, Zhi-Cheng.

In: Cell Adhesion and Migration, Vol. 7, No. 5, 2013, p. 404 - 407.

Research output: Contribution to journalArticleOther

TY - JOUR

T1 - Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis

AU - Hou, Zong-liu

AU - Liu, Ying

AU - Mao, Xi-Hong

AU - Wei, Chuan-yu

AU - Meng, Ming-yao

AU - Liu, Yung-hong

AU - Yang, Zara Zhuyun

AU - Zhu, Hongmei

AU - Short, Martin

AU - Bernard, Claude Charles Andre

AU - Xiao, Zhi-Cheng

PY - 2013

Y1 - 2013

N2 - There is currently great interest in the use of mesenchymal stem cells as a therapy for multiple sclerosis with potential to both ameliorate inflammatory processes as well as improve regeneration and repair. Although most clinical studies have used autologous bone marrow-derived mesenchymal stem cells, other sources such as allogeneic umbilical cord-derived cells may provide a more accessible and practical supply of cells for transplantation. In this case report we present the treatment of aggressive multiple sclerosis with multiple allogenic human umbilical cord-derived mesenchymal stem cell and autologous bone marrow-derived mesenchymal stem cells over a 4 y period. The treatments were tolerated well with no significant adverse events. Clinical and radiological disease appeared to be suppressed following the treatments and support the expansion of mesenchymal stem cell transplantation into clinical trials as a potential novel therapy for patients with aggressive multiple sclerosis.

AB - There is currently great interest in the use of mesenchymal stem cells as a therapy for multiple sclerosis with potential to both ameliorate inflammatory processes as well as improve regeneration and repair. Although most clinical studies have used autologous bone marrow-derived mesenchymal stem cells, other sources such as allogeneic umbilical cord-derived cells may provide a more accessible and practical supply of cells for transplantation. In this case report we present the treatment of aggressive multiple sclerosis with multiple allogenic human umbilical cord-derived mesenchymal stem cell and autologous bone marrow-derived mesenchymal stem cells over a 4 y period. The treatments were tolerated well with no significant adverse events. Clinical and radiological disease appeared to be suppressed following the treatments and support the expansion of mesenchymal stem cell transplantation into clinical trials as a potential novel therapy for patients with aggressive multiple sclerosis.

UR - http://www.ncbi.nlm.nih.gov/pubmed/24192520

U2 - 10.4161/cam.26941

DO - 10.4161/cam.26941

M3 - Article

VL - 7

SP - 404

EP - 407

JO - Cell Adhesion and Migration

JF - Cell Adhesion and Migration

SN - 1933-6918

IS - 5

ER -